Q&A

Expert Q&A
Expert Q&A
10/15/2015
In part 1 of this interview, Estelle Everett, MD, explores the impact of provider bias and clinic barriers on access to diabetes technology. She shares how improving access to tools like continuous glucose...
10/15/2015
Expert Q&A
Expert Q&A
10/15/2015
In part 1 of this interview, Estelle Everett, MD, explores the impact of provider bias and clinic barriers on access to diabetes technology. She shares how improving access to tools like continuous glucose...
10/15/2015
Expert Q&A
Expert Q&A
10/15/2015
In part 1 of this interview, Estelle Everett, MD, explores the impact of provider bias and clinic barriers on access to diabetes technology. She shares how improving access to tools like continuous glucose...
10/15/2015
Neurology
Neurology
09/27/2015
Raman Malhotra, MD, answered our questions about the association between circadian rhythm and neurodegenerative diseases, the most common neurodegenerative diseases, and more.
09/27/2015
Genetics
Genetics
09/18/2015
Alison Goate, DPhil, answered our questions about her research on the role of genetics in Alzheimer disease onset, a topic she will also be presenting at 144th Annual Meeting of the American Neurological...
09/18/2015
Screening
Screening
04/29/2015
Steven DeMeester, MD, from the Oregon Clinic, answers our questions about his research that compared standard biopsies with the wide-area transepithelial sampling brush for detecting intestinal metaplasia...
04/29/2015
Q&As
Q&As
06/05/2012
Edward Shahady, MD; Tara Dall, MD; Steven Milligan, MD
<p>As the chair for the Cardiometabolic Risk Summit, which will be held this coming September in Las Vegas, I am very excited about this meeting and our partnership...
06/05/2012
Liver Disease
Liver Disease
03/03/2012
Jennifer Flemming, MD, MAS, from KHSC Kingston Health Sciences Centre, answers our questions about her research on the association between pregnancy and liver decompensation among women with cirrhosis. ...
03/03/2012
COPD
COPD
04/30/2011
Thomas L. Petty, MD
Drugs on the horizon include the phosphodiesterase-4 inhibitors, 2 of which—cilomilast and roflumilast—are in phase 3 clinical trials.
04/30/2011
Q&As
Q&As
04/30/2011
Donald G. Vidt, MD
Hypertensive crises encompass a spectrum of clinical situations that have in common elevated blood pressure (BP) and progressive or impending target organ damage.
04/30/2011